Cell death induced by NLRP3–palmitate axis impairs pulmonary damage tolerance and aggravates immunopathology during obesity‐tuberculosis comorbidity

A low‐grade and persistent inflammation, which is the hallmark of obesity, requires the participation of NLRP3 and cell death. During Mycobacterium tuberculosis infection, NLRP3 signaling is important for bacterial killing by macrophages in vitro but was shown to be dispensable for host protection in vivo. We hypothesized that during obesity‐tuberculosis (TB) comorbidity, NLRP3 signaling might play a detrimental role by inducing excessive inflammation. We employed a model of high‐fat‐diet‐induced obesity, followed by M. tuberculosis infection in C57BL/6 mice. Obese mice presented increased susceptibility to infection and pulmonary immunopathology compared to lean mice. Using treatment with NLRP3 antagonist and Nlrp3−/− mice, we showed that NLRP3 signaling promoted cell death, with no effect in bacterial loads. The levels of palmitate were higher in the lungs of obese infected mice compared to lean counterparts, and we observed that this lipid increased M. tuberculosis‐induced macrophage death in vitro, which was dependent on NLRP3 and caspase‐1. At the chronic phase, although lungs of obese Nlrp3−/− mice showed an indication of granuloma formation compared to obese wild‐type mice, there was no difference in the bacterial load. Our findings indicate that NLRP3 may be a potential target for host‐directed therapy to reduce initial and severe inflammation‐mediated disease and to treat comorbidity‐associated TB. © 2022 The Pathological Society of Great Britain and Ireland.

[1]  Jiaqi Dong,et al.  Association between body mass index and newly diagnosed drug-resistant pulmonary tuberculosis in Shandong, China from 2004 to 2019 , 2021, BMC Pulmonary Medicine.

[2]  S. Rhee,et al.  Body Mass Index, Diabetes, and Risk of Tuberculosis: A Retrospective Cohort Study , 2021, Frontiers in Nutrition.

[3]  A. Zalin,et al.  Managing obesity in people with type 2 diabetes. , 2021, Clinical medicine.

[4]  Sara B Ellinwood,et al.  Mycobacterium tuberculosis inhibits the NLRP3 inflammasome activation via its phosphokinase PknF , 2021, PLoS pathogens.

[5]  Sandra Patricia Palma Albornoz,et al.  Obesity-Induced Dysbiosis Exacerbates IFN-γ Production and Pulmonary Inflammation in the Mycobacterium tuberculosis Infection , 2021, Cells.

[6]  M. M. Ogusku,et al.  Combining Host Genetics and Functional Analysis to Depict Inflammasome Contribution in Tuberculosis Susceptibility and Outcome in Endemic Areas , 2020, Frontiers in Immunology.

[7]  Irah L. King,et al.  Editorial: Evolving Mechanisms of Disease Tolerance , 2019, Frontiers in Immunology.

[8]  P. Salgame,et al.  Infection resisters: targets of new research for uncovering natural protective immunity against Mycobacterium tuberculosis , 2019, F1000Research.

[9]  H. Stenmark,et al.  Plasma membrane damage causes NLRP3 activation and pyroptosis during Mycobacterium tuberculosis infection , 2019, bioRxiv.

[10]  A. Sher,et al.  A major role for ferroptosis in Mycobacterium tuberculosis–induced cell death and tissue necrosis , 2019, The Journal of experimental medicine.

[11]  S. Beverley,et al.  Leishmania Lipophosphoglycan Triggers Caspase-11 and the Non-canonical Activation of the NLRP3 Inflammasome , 2019, Cell reports.

[12]  J. Alves-Filho,et al.  CCR4-dependent reduction in the number and suppressor function of CD4+Foxp3+ cells augments IFN-γ-mediated pulmonary inflammation and aggravates tuberculosis pathogenesis , 2018, Cell Death & Disease.

[13]  E. Kaufmann,et al.  Beyond Killing Mycobacterium tuberculosis: Disease Tolerance , 2018, Front. Immunol..

[14]  G. Cavalli,et al.  Anakinra Therapy for Non-cancer Inflammatory Diseases , 2018, Front. Pharmacol..

[15]  S. Kim,et al.  Association of body mass index with incident tuberculosis in Korea , 2018, PloS one.

[16]  Hsien-Ho Lin,et al.  Association of Obesity, Diabetes, and Risk of Tuberculosis: Two Population-Based Cohorts , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  J. Critchley,et al.  Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes: Part 1: Epidemiology and Clinical Management. , 2017, Chest.

[18]  Pawan Kumar IFNγ-producing CD4+ T lymphocytes: the double-edged swords in tuberculosis , 2017, Clinical and Translational Medicine.

[19]  A. Afolayan,et al.  Lifestyle factors and co-morbidities associated with obesity and overweight in Nkonkobe Municipality of the Eastern Cape, South Africa , 2017, Journal of Health, Population and Nutrition.

[20]  S. Babu,et al.  Influence of diabetes mellitus on immunity to human tuberculosis , 2017, Immunology.

[21]  Xinchun Chen,et al.  Nitric oxide prevents a pathogen permissive granulocytic inflammation during tuberculosis , 2017, Nature Microbiology.

[22]  D. Zamboni,et al.  Inflammasome biology taught by Legionella pneumophila , 2017, Journal of leukocyte biology.

[23]  W. Lu,et al.  Association of Body Mass Index with the Tuberculosis Infection: a Population-based Study among 17796 Adults in Rural China , 2017, Scientific Reports.

[24]  S. Ramos,et al.  M2 macrophages or IL-33 treatment attenuate ongoing Mycobacterium tuberculosis infection , 2017, Scientific Reports.

[25]  A. Klip,et al.  Saturated fatty acids activate caspase-4/5 in human monocytes, triggering IL-1β and IL-18 release. , 2016, American journal of physiology. Endocrinology and metabolism.

[26]  M. M. Ogusku,et al.  Inflammasome genetics contributes to the development and control of active pulmonary tuberculosis. , 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[27]  V. Dixit,et al.  NLRP3 recruitment by NLRC4 during Salmonella infection , 2016, The Journal of experimental medicine.

[28]  A. F. Gembre,et al.  Genetic background affects the expansion of macrophage subsets in the lungs of Mycobacterium tuberculosis‐infected hosts , 2016, Immunology.

[29]  S. Legrand-Poels,et al.  Free fatty acids as modulators of the NLRP3 inflammasome in obesity/type 2 diabetes. , 2014, Biochemical pharmacology.

[30]  E. Israel,et al.  IL-17 producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity , 2014 .

[31]  James L. Mueller,et al.  Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. , 2013, The Journal of clinical investigation.

[32]  A. Torrecilhas,et al.  NLRP3 Controls Trypanosoma cruzi Infection through a Caspase-1-Dependent IL-1R-Independent NO Production , 2013, PLoS neglected tropical diseases.

[33]  T. Nutman,et al.  Expansion of pathogen-specific T-helper 1 and T-helper 17 cells in pulmonary tuberculosis with coincident type 2 diabetes mellitus. , 2013, The Journal of infectious diseases.

[34]  Daniel E. Zak,et al.  Caspase-11 Protects Against Bacteria That Escape the Vacuole , 2013, Science.

[35]  M. Jeyanathan,et al.  Within the Enemy’s Camp: contribution of the granuloma to the dissemination, persistence and transmission of Mycobacterium tuberculosis , 2013, Front. Immun..

[36]  T. Kanneganti,et al.  Immunological complications of obesity , 2012, Nature Immunology.

[37]  Ruslan Medzhitov,et al.  Disease Tolerance as a Defense Strategy , 2012, Science.

[38]  J. Tschopp,et al.  Activation of the NLRP3 inflammasome by Mycobacterium tuberculosis is uncoupled from susceptibility to active tuberculosis , 2012, European journal of immunology.

[39]  F. Re,et al.  Role of the Inflammasome, IL-1β, and IL-18 in Bacterial Infections , 2011, TheScientificWorldJournal.

[40]  L. Joosten,et al.  Inflammasome is a central player in the induction of obesity and insulin resistance , 2011, Proceedings of the National Academy of Sciences.

[41]  E. Latz,et al.  NLRP3 inflammasomes link inflammation and metabolic disease. , 2011, Trends in immunology.

[42]  R. Eckel,et al.  Obesity and type 2 diabetes: what can be unified and what needs to be individualized? , 2011, The Journal of clinical endocrinology and metabolism.

[43]  Denis Gris,et al.  Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin signaling , 2011, Nature Immunology.

[44]  W. Jacobs Jr,et al.  Critical role for NLRP3 in necrotic death triggered by Mycobacterium tuberculosis , 2011, Cellular microbiology.

[45]  A. Sher,et al.  CD4 T Cells Promote Rather than Control Tuberculosis in the Absence of PD-1–Mediated Inhibition , 2011, The Journal of Immunology.

[46]  J. Flynn,et al.  HIV-1/Mycobacterium tuberculosis Coinfection Immunology: How Does HIV-1 Exacerbate Tuberculosis? , 2011, Infection and Immunity.

[47]  E. Ravussin,et al.  The NALP3/NLRP3 Inflammasome Instigates Obesity-Induced Autoinflammation and Insulin Resistance , 2010, Nature Medicine.

[48]  S. Behar,et al.  Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy? , 2010, Nature Reviews Microbiology.

[49]  M. Braunstein,et al.  Granuloma Formation and Host Defense in Chronic Mycobacterium tuberculosis Infection Requires PYCARD/ASC but Not NLRP3 or Caspase-1 , 2010, PloS one.

[50]  N. Hacohen,et al.  Mycobacterium tuberculosis protein ESAT‐6 is a potent activator of the NLRP3/ASC inflammasome , 2010, Cellular microbiology.

[51]  D. Underhill,et al.  Faculty Opinions recommendation of Caspase-1 independent IL-1beta production is critical for host resistance to mycobacterium tuberculosis and does not require TLR signaling in vivo. , 2010 .

[52]  A. Sher,et al.  Cutting Edge: Caspase-1 Independent IL-1β Production Is Critical for Host Resistance to Mycobacterium tuberculosis and Does Not Require TLR Signaling In Vivo , 2010, The Journal of Immunology.

[53]  R. Bibiloni,et al.  Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet–Induced Obesity and Diabetes in Mice , 2008, Diabetes.

[54]  J. Flier,et al.  TLR4 links innate immunity and fatty acid-induced insulin resistance. , 2006, The Journal of clinical investigation.

[55]  F. Bäckhed,et al.  Obesity alters gut microbial ecology. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[56]  H. Minuk,et al.  Metabolic syndrome. , 2005, Journal of insurance medicine.

[57]  C. Dolea,et al.  World Health Organization , 1949, International Organization.